CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published ahead of print on June 4, 2008
Clinical Journal of the American Society of Nephrology
© 2008 American Society of Nephrology
doi: 10.2215/CJN.00500108
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Bollée, G.
Right arrow Articles by Noël, L.-H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bollée, G.
Right arrow Articles by Noël, L.-H.

Received January 28, 2008
Accepted on May 5, 2008

ORIGINAL ARTICLES

High-Dosage Intravenous Immunoglobulin–Associated Macrovacuoles Are Associated with Chronic Tubulointerstitial Lesion Worsening in Renal Transplant Recipients

Guillaume Bollée *1, Dany Anglicheau {dagger}, Alexandre Loupy {dagger}, Julien Zuber {dagger}, Natacha Patey *, Duncan Mac Gregor *, Frank Martinez {dagger}, Marie-France Mamzer-Bruneel {dagger}, Renaud Snanoudj {dagger}, Eric Thervet {dagger}, Christophe Legendre {dagger}, and Laure-Hélène Noël *

*Laboratoire d’Anatomie Pathologique and {dagger}Service de Transplantation Rénale et de Soins Intensifs, Hôpital Necker, APHP, and Université René Descartes, Paris, France


1 To whom correspondence should be addressed. E-mail: guillaume.bollee{at}nck.aphp.fr.


   Abstract

Background and objectives: Intravenous immunoglobulins (IVIg) may induce acute renal failure associated with tubular vacuolization. Although the use of IVIg is increasing in kidney transplantation, their impact on graft histology and function remains unknown.

Design, setting, participants, & measurements: Twenty-seven kidney transplant recipients who had high immunologic risk and were treated with four courses of IVIg after transplantation were studied retrospectively at a transplant center, and findings were compared with those of 27 control subjects. Protocol kidney biopsies were performed at time of transplantation and at 3 mo and 1 yr after transplantation.

Results: No episode of IVIg-related acute renal failure occurred. Nevertheless, screening biopsies revealed the presence of "microvacuoles" and "macrovacuoles." Widespread microvacuolizations were often detected (70%) on preimplantation biopsy and not associated with IVIg. Macrovacuoles, which were absent on preimplantation biopsies, were observed exclusively in IVIg-treated patients. Macrovacuoles among IVIg-treated patients were seen in kidneys from older donors and were associated with chronic tubulointerstitial changes at 3 mo, with similar trends at 1 yr. Macrovacuoles were associated with lower creatinine clearance at last follow-up in IVIg-treated patients.

Conclusions: IVIg frequently induce tubular macrovacuoles in kidney transplant recipients. These are more frequently observed in grafts from older donors, suggesting a higher vulnerability to IVIg. These data suggest a deleterious impact of IVIg-induced macrovacuoles on chronic tubulointerstitial changes and long-term renal function.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Society of Nephrology.